The Twilight Therapy to Rejuvenate Your Cells

Infusions with a blood-derived protein could regenerate aging cells. Read this free report on “vampire therapy” and two other promising anti-aging treatments biotech firms are currently working on…

A protein expressed by the growth differentiation factor 11 (GDF11) gene could be the secret to human longevity.

The downside: So far it’s only been tested on mice, and if marketed, the treatment might be forbiddingly expensive.

There are, however, two other promising and much more affordable therapies biotech firms are currently working on…

In this exclusive report, biotech expert Patrick Cox, in partnership with Mauldin Economics, discusses the treatments that could prove to be the long-sought building blocks for a lifespan rivaling that of the biblical Methuselah.

Find out in this must-read report:

Geopolitical Futures Annual Forecast 2016

    The insidious strategy cancer tumors use to fool the immune system… and the new biotech revelation that could stop them from growing and restore cancer-ridden organs to a youthful, healthy condition.


    Will “vampire therapy” save us from aging? Pros and cons of the amazing rejuvenation treatment first described by a famous science-fiction author… 75 years ago.


    Legalizing GHRH: The healthier successor of human growth hormone (hGH) is keeping Australian farm animals in top shape… and the reason why we can’t get it here yet.

Patrick Cox’s fascinating report gives you all the details on these three revolutionary new treatments from the biotech labs.

Don’t miss reading about these therapies and their near-miraculous regenerative effects on aging cells.


Enter your email address below for instant access.


Your privacy is important to us. We will never give your email address to third parties.

As our thank-you gift, you will also receive Patrick Cox’s Tech Digest, a weekly snapshot of the latest biotech breakthroughs in life-extension and anti-aging research. If you want to stop receiving this free e-letter, you can opt out at any time.

Mauldin Economics gives its subscribers access to some of the brightest minds in economics and investing, uncovering tomorrow’s trends and market leaders that make today’s smart investment choices.

Patrick Cox has written over 200 editorials for USA Today, has appeared in the Wall Street Journal, and on CNN's Crossfire. He consults with Nobel Prize-winning economists and scientists and investigates transformational, wealth-building tech companies to assess their profit potential.